Dyadic and Scripps Research Team Up on Hantavirus Antibody and Vaccine Development
Event summary
- Dyadic International and Scripps Research are collaborating to develop monoclonal antibody and vaccine candidates targeting hantaviruses, including the Andes virus, which causes Hantavirus Pulmonary Syndrome (HPS).
- The collaboration leverages Dyadic’s C1 platform for rapid development, high-productivity microbial fermentation, and large-scale manufacturing of biologics.
- Dyadic’s C1 platform has previously demonstrated the ability to produce monoclonal antibodies with comparable binding, neutralization, and efficacy characteristics to traditional mammalian expression systems.
- The partnership builds on Dyadic’s prior work on Andes virus monoclonal antibodies and Scripps Research’s expertise in structure-based protein designs.
The big picture
The collaboration between Dyadic and Scripps Research underscores the growing emphasis on pandemic preparedness and the need for scalable, cost-effective biologic manufacturing. Recent outbreaks of hantavirus and Ebola have highlighted the importance of rapid response capabilities in infectious disease management. Dyadic’s C1 platform, with its demonstrated ability to produce high-quality biologics, positions the company as a key player in the biopharmaceutical sector, particularly in the context of emerging infectious disease threats.
What we're watching
- Technological Validation
- How Dyadic’s C1 platform will perform in producing monoclonal antibodies and vaccines for hantaviruses compared to traditional methods.
- Funding Dynamics
- Whether the collaboration will secure additional non-dilutive funding to support further development activities.
- Market Adoption
- The pace at which Dyadic can commercialize its C1 platform for broader infectious disease preparedness applications.
Related topics